ICLR241220P270000
- 11.80
- 0.000.00%
Icon PLC Newsroom
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $260
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
Icon Analyst Ratings
Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $284
Express News | ICON PLC : Truist Securities Cuts Target Price to $284 From $295
Express News | ICON PLC - Appoints Barry Balfe as COO
ICON Announces Appointment of Chief Operating Officer
The WuXi system welcomes a bullish trend! What is the next catalyst?
Many institutions have indicated that this may be a critical juncture for the healthcare sector.
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
ICON Public Limited Company (ICLR) Fell Along With Peers
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption
Nephron Initiates Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $280
Nephron Upgrades ICON to Buy, Price Target Is $280
Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 48%?
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Baird Upgrades Icon PLC(ICLR.US) to Buy Rating, Raises Target Price to $242
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound?
Should You Retain Your Conviction in Icon Plc (ICLR)?
Icon Is Maintained at Neutral by Baird